![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CAV1 |
Gene summary for CAV1 |
![]() |
Gene information | Species | Human | Gene symbol | CAV1 | Gene ID | 857 |
Gene name | caveolin 1 | |
Gene Alias | BSCL3 | |
Cytomap | 7q31.2 | |
Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | A0A024R757 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
857 | CAV1 | AEH-subject1 | Human | Endometrium | AEH | 2.16e-19 | -4.71e-01 | -0.3059 |
857 | CAV1 | AEH-subject2 | Human | Endometrium | AEH | 1.47e-08 | -3.71e-01 | -0.2525 |
857 | CAV1 | AEH-subject3 | Human | Endometrium | AEH | 3.63e-11 | -4.05e-01 | -0.2576 |
857 | CAV1 | AEH-subject4 | Human | Endometrium | AEH | 9.28e-08 | -4.09e-01 | -0.2657 |
857 | CAV1 | AEH-subject5 | Human | Endometrium | AEH | 4.71e-10 | -4.02e-01 | -0.2953 |
857 | CAV1 | EEC-subject1 | Human | Endometrium | EEC | 1.83e-20 | -5.04e-01 | -0.2682 |
857 | CAV1 | EEC-subject2 | Human | Endometrium | EEC | 1.87e-20 | -4.94e-01 | -0.2607 |
857 | CAV1 | EEC-subject3 | Human | Endometrium | EEC | 3.78e-12 | -2.54e-01 | -0.2525 |
857 | CAV1 | EEC-subject4 | Human | Endometrium | EEC | 1.30e-07 | -3.62e-01 | -0.2571 |
857 | CAV1 | EEC-subject5 | Human | Endometrium | EEC | 4.57e-16 | -4.81e-01 | -0.249 |
857 | CAV1 | GSM5276934 | Human | Endometrium | EEC | 6.49e-09 | 4.43e-01 | -0.0913 |
857 | CAV1 | GSM5276935 | Human | Endometrium | EEC | 1.17e-11 | -4.82e-01 | -0.123 |
857 | CAV1 | GSM5276937 | Human | Endometrium | EEC | 1.54e-46 | 1.05e+00 | -0.0897 |
857 | CAV1 | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 1.01e-16 | -5.16e-01 | -0.1869 |
857 | CAV1 | GSM6177620_NYU_UCEC1_lib2_lib2 | Human | Endometrium | EEC | 5.84e-16 | -5.24e-01 | -0.1875 |
857 | CAV1 | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 4.95e-19 | -5.26e-01 | -0.1883 |
857 | CAV1 | GSM6177621_NYU_UCEC2_lib1_lib1 | Human | Endometrium | EEC | 1.90e-25 | -5.18e-01 | -0.1934 |
857 | CAV1 | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 6.93e-28 | -5.13e-01 | -0.1917 |
857 | CAV1 | GSM6177622_NYU_UCEC3_lib2_lib2 | Human | Endometrium | EEC | 2.42e-28 | -5.39e-01 | -0.1916 |
857 | CAV1 | GSM6177623_NYU_UCEC3_Vis | Human | Endometrium | EEC | 9.78e-11 | -4.34e-01 | -0.1269 |
Page: 1 2 3 4 5 6 7 8 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000193319 | Oral cavity | OSCC | negative regulation of protein phosphorylation | 191/7305 | 342/18723 | 1.58e-10 | 4.62e-09 | 191 |
GO:003139720 | Oral cavity | OSCC | negative regulation of protein ubiquitination | 61/7305 | 83/18723 | 1.78e-10 | 5.17e-09 | 61 |
GO:003367317 | Oral cavity | OSCC | negative regulation of kinase activity | 140/7305 | 237/18723 | 2.74e-10 | 7.57e-09 | 140 |
GO:190589720 | Oral cavity | OSCC | regulation of response to endoplasmic reticulum stress | 60/7305 | 82/18723 | 3.38e-10 | 9.11e-09 | 60 |
GO:000646918 | Oral cavity | OSCC | negative regulation of protein kinase activity | 127/7305 | 212/18723 | 5.21e-10 | 1.37e-08 | 127 |
GO:005123518 | Oral cavity | OSCC | maintenance of location | 182/7305 | 327/18723 | 6.16e-10 | 1.58e-08 | 182 |
GO:004854520 | Oral cavity | OSCC | response to steroid hormone | 186/7305 | 339/18723 | 1.86e-09 | 4.42e-08 | 186 |
GO:003250710 | Oral cavity | OSCC | maintenance of protein location in cell | 49/7305 | 65/18723 | 2.61e-09 | 6.03e-08 | 49 |
GO:004518520 | Oral cavity | OSCC | maintenance of protein location | 65/7305 | 94/18723 | 3.00e-09 | 6.88e-08 | 65 |
GO:19033227 | Oral cavity | OSCC | positive regulation of protein modification by small protein conjugation or removal | 88/7305 | 138/18723 | 3.24e-09 | 7.39e-08 | 88 |
GO:190165316 | Oral cavity | OSCC | cellular response to peptide | 194/7305 | 359/18723 | 4.31e-09 | 9.57e-08 | 194 |
GO:005212620 | Oral cavity | OSCC | movement in host environment | 106/7305 | 175/18723 | 5.84e-09 | 1.26e-07 | 106 |
GO:190332120 | Oral cavity | OSCC | negative regulation of protein modification by small protein conjugation or removal | 65/7305 | 95/18723 | 5.88e-09 | 1.26e-07 | 65 |
GO:005109920 | Oral cavity | OSCC | positive regulation of binding | 105/7305 | 173/18723 | 5.88e-09 | 1.26e-07 | 105 |
GO:20012449 | Oral cavity | OSCC | positive regulation of intrinsic apoptotic signaling pathway | 44/7305 | 58/18723 | 1.22e-08 | 2.48e-07 | 44 |
GO:20012389 | Oral cavity | OSCC | positive regulation of extrinsic apoptotic signaling pathway | 38/7305 | 48/18723 | 1.56e-08 | 3.12e-07 | 38 |
GO:190165419 | Oral cavity | OSCC | response to ketone | 114/7305 | 194/18723 | 1.82e-08 | 3.60e-07 | 114 |
GO:003297020 | Oral cavity | OSCC | regulation of actin filament-based process | 209/7305 | 397/18723 | 1.89e-08 | 3.72e-07 | 209 |
GO:004873220 | Oral cavity | OSCC | gland development | 226/7305 | 436/18723 | 2.78e-08 | 5.39e-07 | 226 |
GO:003010016 | Oral cavity | OSCC | regulation of endocytosis | 121/7305 | 211/18723 | 4.74e-08 | 8.80e-07 | 121 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0502020 | Endometrium | AEH | Prion disease | 110/1197 | 273/8465 | 2.39e-27 | 2.44e-25 | 1.78e-25 | 110 |
hsa0510026 | Endometrium | AEH | Bacterial invasion of epithelial cells | 32/1197 | 77/8465 | 3.28e-09 | 5.91e-08 | 4.33e-08 | 32 |
hsa0541625 | Endometrium | AEH | Viral myocarditis | 27/1197 | 60/8465 | 6.98e-09 | 1.13e-07 | 8.30e-08 | 27 |
hsa0451015 | Endometrium | AEH | Focal adhesion | 58/1197 | 203/8465 | 4.99e-08 | 7.37e-07 | 5.39e-07 | 58 |
hsa0541826 | Endometrium | AEH | Fluid shear stress and atherosclerosis | 43/1197 | 139/8465 | 2.47e-07 | 3.49e-06 | 2.55e-06 | 43 |
hsa0520518 | Endometrium | AEH | Proteoglycans in cancer | 53/1197 | 205/8465 | 5.43e-06 | 6.53e-05 | 4.78e-05 | 53 |
hsa0414420 | Endometrium | AEH | Endocytosis | 56/1197 | 251/8465 | 2.58e-04 | 2.15e-03 | 1.57e-03 | 56 |
hsa05020110 | Endometrium | AEH | Prion disease | 110/1197 | 273/8465 | 2.39e-27 | 2.44e-25 | 1.78e-25 | 110 |
hsa05100111 | Endometrium | AEH | Bacterial invasion of epithelial cells | 32/1197 | 77/8465 | 3.28e-09 | 5.91e-08 | 4.33e-08 | 32 |
hsa05416111 | Endometrium | AEH | Viral myocarditis | 27/1197 | 60/8465 | 6.98e-09 | 1.13e-07 | 8.30e-08 | 27 |
hsa0451016 | Endometrium | AEH | Focal adhesion | 58/1197 | 203/8465 | 4.99e-08 | 7.37e-07 | 5.39e-07 | 58 |
hsa05418112 | Endometrium | AEH | Fluid shear stress and atherosclerosis | 43/1197 | 139/8465 | 2.47e-07 | 3.49e-06 | 2.55e-06 | 43 |
hsa0520519 | Endometrium | AEH | Proteoglycans in cancer | 53/1197 | 205/8465 | 5.43e-06 | 6.53e-05 | 4.78e-05 | 53 |
hsa04144110 | Endometrium | AEH | Endocytosis | 56/1197 | 251/8465 | 2.58e-04 | 2.15e-03 | 1.57e-03 | 56 |
hsa0502025 | Endometrium | EEC | Prion disease | 111/1237 | 273/8465 | 1.01e-26 | 8.27e-25 | 6.16e-25 | 111 |
hsa0541626 | Endometrium | EEC | Viral myocarditis | 28/1237 | 60/8465 | 2.81e-09 | 5.77e-08 | 4.30e-08 | 28 |
hsa0541827 | Endometrium | EEC | Fluid shear stress and atherosclerosis | 45/1237 | 139/8465 | 7.76e-08 | 1.22e-06 | 9.07e-07 | 45 |
hsa0510027 | Endometrium | EEC | Bacterial invasion of epithelial cells | 30/1237 | 77/8465 | 1.26e-07 | 1.88e-06 | 1.40e-06 | 30 |
hsa0451024 | Endometrium | EEC | Focal adhesion | 58/1237 | 203/8465 | 1.61e-07 | 2.30e-06 | 1.71e-06 | 58 |
hsa0520524 | Endometrium | EEC | Proteoglycans in cancer | 52/1237 | 205/8465 | 3.01e-05 | 3.19e-04 | 2.38e-04 | 52 |
Page: 1 2 3 4 5 6 7 8 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CAV1 | SNV | Missense_Mutation | c.62A>T | p.Gln21Leu | p.Q21L | Q03135 | protein_coding | deleterious_low_confidence(0.01) | benign(0.054) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
CAV1 | SNV | Missense_Mutation | c.32N>C | p.Gly11Ala | p.G11A | Q03135 | protein_coding | tolerated_low_confidence(0.07) | benign(0.005) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
CAV1 | SNV | Missense_Mutation | c.529N>C | p.Glu177Gln | p.E177Q | Q03135 | protein_coding | deleterious(0.01) | possibly_damaging(0.588) | TCGA-C8-A1HM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | CR | |
CAV1 | SNV | Missense_Mutation | novel | c.386N>A | p.Ala129Glu | p.A129E | Q03135 | protein_coding | tolerated(0.05) | possibly_damaging(0.506) | TCGA-E9-A2JS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cyclophosphamide | PD |
CAV1 | SNV | Missense_Mutation | novel | c.418N>A | p.Glu140Lys | p.E140K | Q03135 | protein_coding | tolerated(0.2) | benign(0.005) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
CAV1 | SNV | Missense_Mutation | c.286N>G | p.Lys96Glu | p.K96E | Q03135 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-CK-5916-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
CAV1 | SNV | Missense_Mutation | novel | c.517A>G | p.Asn173Asp | p.N173D | Q03135 | protein_coding | tolerated(0.32) | benign(0.003) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CAV1 | SNV | Missense_Mutation | novel | c.505A>T | p.Asn169Tyr | p.N169Y | Q03135 | protein_coding | deleterious(0.04) | possibly_damaging(0.467) | TCGA-AJ-A23O-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CAV1 | SNV | Missense_Mutation | novel | c.190N>A | p.Val64Ile | p.V64I | Q03135 | protein_coding | tolerated(0.17) | possibly_damaging(0.456) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
CAV1 | SNV | Missense_Mutation | rs143730366 | c.436C>T | p.Arg146Cys | p.R146C | Q03135 | protein_coding | deleterious(0.01) | probably_damaging(0.978) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
857 | CAV1 | TRANSPORTER, KINASE | ETHANOL | ALCOHOL | 15845868 | |
857 | CAV1 | TRANSPORTER, KINASE | TESTOSTERONE | TESTOSTERONE | 11389065 |
Page: 1 |